SCHOTT Pharma AG & Co KgaA
XETRA:1SXP

Watchlist Manager
SCHOTT Pharma AG & Co KgaA Logo
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Watchlist
Price: 26.62 EUR 1.53% Market Closed
Market Cap: 4B EUR
Have any thoughts about
SCHOTT Pharma AG & Co KgaA?
Write Note

SCHOTT Pharma AG & Co KgaA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SCHOTT Pharma AG & Co KgaA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Income from Continuing Operations
€151.9m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Evotec SE
XETRA:EVT
Income from Continuing Operations
-€171.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-20%
Gerresheimer AG
XETRA:GXI
Income from Continuing Operations
€116.3m
CAGR 3-Years
9%
CAGR 5-Years
-10%
CAGR 10-Years
4%
No Stocks Found

SCHOTT Pharma AG & Co KgaA
Glance View

Market Cap
4B EUR
Industry
Life Sciences Tools & Services

SCHOTT Pharma AG & Co KgaA is a DE-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Mainz, Hessen. The company went IPO on 2023-09-28. SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The firm's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.

1SXP Intrinsic Value
34.05 EUR
Undervaluation 22%
Intrinsic Value
Price

See Also

What is SCHOTT Pharma AG & Co KgaA's Income from Continuing Operations?
Income from Continuing Operations
151.9m EUR

Based on the financial report for Sep 30, 2023, SCHOTT Pharma AG & Co KgaA's Income from Continuing Operations amounts to 151.9m EUR.

What is SCHOTT Pharma AG & Co KgaA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
25%

Over the last year, the Income from Continuing Operations growth was 21%. The average annual Income from Continuing Operations growth rates for SCHOTT Pharma AG & Co KgaA have been 25% over the past three years .

Back to Top